Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of “Moderate Buy” by Analysts

Personalis, Inc. (NASDAQ:PSNL) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

Several research analysts have weighed in on PSNL shares. Morgan Stanley lowered their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research lowered their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Needham & Company LLC upped their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th.

Insider Activity

In other Personalis news, CEO Christopher M. Hall sold 80,091 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This represents a 25.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,387,984.33. This trade represents a 16.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,799 shares of company stock worth $2,031,692 over the last 90 days. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after purchasing an additional 1,655 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares in the last quarter. Howland Capital Management LLC lifted its holdings in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC lifted its holdings in shares of Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after purchasing an additional 3,851 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Trading Up 8.1%

Shares of PSNL opened at $10.54 on Friday. The firm’s 50-day moving average is $7.82 and its two-hundred day moving average is $8.22. Personalis has a twelve month low of $3.84 and a twelve month high of $12.53. The firm has a market capitalization of $1.10 billion, a P/E ratio of -10.33 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Analysts predict that Personalis will post -1.06 EPS for the current year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.